



Receipt
FILED COPY
PATENT

Attorney Docket No: 28967/35061A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
RECEIVING OFFICE

Applicants: K. Alitalo, S. Yla-Herttuala,
M.O. Hiltunen, M.M. Jeltsch, and M.G.
Achen.

US Serial No.: 09/427,657

Filed: 26 October 1999

For: Use of VEGF-C or VEGF-D Gene
or Protein to Prevent Restenosis.

Group Art Unit: 1633

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper is being deposited with
the United States Postal Service as first class mail
postage prepaid, on **January 19, 2000**, in an envelope
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.


Richard Zimmermann

REQUEST FOR ISSUANCE OF A CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Dear Sirs:

The Applicants respectfully request issuance of a corrected filing receipt. The filing receipt, a copy of which is attached hereto, fails to indicate the claimed priority application which is U.S. Provisional Application No.: 60/105,587, filed October 26, 1998. (See patent application at page 1 and inventors' declaration, copies of which are attached.)

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:


David A. Gass
Reg. No. 38,153

January 19, 2000



- 1 -

USE OF VEGF-C OR VEGF-D GENE OR PROTEIN TO PREVENT RESTENOSIS

This application claims priority benefit of United States Provisional Application No. 60/105,587, filed October 26, 1998, incorporated herein by reference.

5

FIELD OF THE INVENTION

The present invention provides materials and methods to prevent stenosis and restenosis of blood vessels, and relates generally to the field of cardiovascular medicine.

BACKGROUND OF THE INVENTION

10 Coronary artery disease constitutes a major cause of morbidity and mortality throughout the world, especially in the United States and Europe. Percutaneous transluminal coronary angioplasty (e.g., balloon angioplasty, with or without intracoronary stenting) is now a common and successful therapy for such disease, performed hundreds of thousands of times per year in the United States alone. However,

15 restenosis occurs in as many as one-third to one-half of such revascularization procedures, usually within six months of the angioplasty procedure. The economic cost of restenosis has been estimated at \$2 billion annually in the United States alone. [Feldman *et al.*, *Cardiovascular Research*, 32: 194-207 (1996), incorporated herein by reference.]

Autopsy and atherectomy studies have identified intimal hyperplasia as the major histologic


20 component of restenotic lesions. [Cerek *et al.*, *Am. J. Cardiol.*, 68: 24C-33C (1991).]

Restenosis also remains a clinical concern in angioplasty that is performed in peripheral blood vessels. Likewise, stenosis is a clinical concern following transplantation of blood vessels (e.g., grafted veins and grafted artificial vessels) for cardiac bypass therapy or for treatment of peripheral ischemia or intermittent claudication,

25 for example (e.g., above-knee femoro-popliteal arterial bypass grafts).

Mazur *et al.*, *Texas Heart Institute Journal*, 21; 104-111 (1994) state that restenosis is primarily a response of the artery to the injury caused by percutaneous coronary angioplasty, which disrupts the intimal layer of endothelial cells and underlying


FILING RECEIPT
CORRECTED



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Offic
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/427,657	10/26/99	1633	\$1,473.00	28967/35061A	4	30	9

MARSHALL O'TOOLE GERSTEIN
MURRAY & BORUN
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO IL 60606-6402



Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) KARI ALITALO, ESPOO, FINLAND; SEppo YLA-HERTTUALA, KUOPIO, FINLAND; MIKKO O. HILTUNEN, KUOPIO, FINLAND; MARKKU M. JELTSCH, HELSINKI, FINLAND; MARC G. ACHEN, VICTORIA, AUSTRALIA.

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 12/01/99
TITLE
USE OF VEGF-C OR VEGF-D GENE OR PROTEIN TO PREVENT RESTENOSIS

PRELIMINARY CLASS: 424



DATA ENTRY BY: MIDDLETON, MATTIE TEAM: 04 DATE: 01/05/00



(See reverse for new important information)